DBP International AB: the subsidiary FarmPharma receives a grant of SEK 300,000

FarmPharma AB (publ), which is a subsidiary of Double Bond Pharmaceutical International AB (publ), have been granted SEK 300,000 by Vinnova in the call “Innovative Startups step 1”. The grant will support ongoing collaboration with Karolinska Institute for the production of starting materials for the company's drug candidate InterferOX.

More about collaboration with Karolinska Institutet: https://mb.cision.com/Main/12720/2985377/1157822.pdf

More about Vinnova: www.vinnova.se

More about FarmPharma: FarmPharma AB (publ) is a subsidiary of Double Bond Pharmaceutical International AB (publ). The company operates in the development and distribution of veterinary products, with a first product for the prevention and treatment of bacterial and viral infections in cattle without the use of antibiotics. For more info: http://www.farmpharma.se/ and https://www.doublebp.com/wp-content/uploads/2020/02/Memorandum-2020-DBP-International-AB.pdf .

Video presentation: https://youtu.be/e1cPSC2PC70

____________________________________________________________________

Full Company Name:   Double Bond Pharmaceutical International AB (publ)

Corporate identity:       556991-6082

Stock short name:       DBP B

Share ISIN code:          SE0007185525

For more info, contact

Igor Lokot, CEO

Homepage: http://www.doublebp.com/

E-mail: info@doublebp.com

Follow us on LinkedIn (https://www.linkedin.com/company/double-bond-pharmaceutical?trk=co-feed-likes-one) and Twitter (https://twitter.com/DoubleBondPharm)!

_______________________________________________________________________________

Information on Double Bond Pharmaceutical International AB

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.